» Articles » PMID: 29531804

Modeling Cancer Using Patient-derived Induced Pluripotent Stem Cells to Understand Development of Childhood Malignancies

Overview
Date 2018 Mar 14
PMID 29531804
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro modeling of complex diseases is now a possibility with the use of patient-derived induced pluripotent stem (iPS) cells. Their stem cell properties, including self-renewal and their potential to virtually differentiate into any cell type, emphasize their importance as a translational tool for modeling disorders that so far have been limited by the unavailability of primary cell lines, animal models, or inaccessible human materials. Around 100 genes with germline mutations have been described to be responsible for cancer predisposition. Familial cancers are usually diagnosed earlier in life since these patients already carry the first transforming hit. Deriving iPS cells from patients suffering from familial cancers provides a valuable tool for understanding the mechanisms underlying pediatric cancer onset and progression since they require less mutation recurrence than adult cancers to develop. At the same time, some familial mutations are found in sporadic cases and are a valuable prognostic tool. Patient-derived iPS cells from germline malignancies can also create new tools in developing specific drugs with more personalized-therapy strategies.

Citing Articles

Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments.

Song S, Nam Y, Rim Y, Ju J, Sohn Y Stem Cell Res Ther. 2024; 15(1):447.

PMID: 39574212 PMC: 11583560. DOI: 10.1186/s13287-024-04065-9.


Spheroids and organoids derived from colorectal cancer as tools for drug screening.

Ahmad Zawawi S, Salleh E, Musa M Explor Target Antitumor Ther. 2024; 5(2):409-431.

PMID: 38745769 PMC: 11090692. DOI: 10.37349/etat.2024.00226.


Human-Induced Pluripotent Stem Cells in Plastic and Reconstructive Surgery.

Hadzimustafic N, DElia A, Shamoun V, Haykal S Int J Mol Sci. 2024; 25(3).

PMID: 38339142 PMC: 10855589. DOI: 10.3390/ijms25031863.


Interconversion of Cancer Cells and Induced Pluripotent Stem Cells.

Sarker D, Xue Y, Mahmud F, Jocelyn J, Sang Q Cells. 2024; 13(2).

PMID: 38247819 PMC: 10814385. DOI: 10.3390/cells13020125.


Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.


References
1.
Lee G, Papapetrou E, Kim H, Chambers S, Tomishima M, Fasano C . Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009; 461(7262):402-6. PMC: 2784695. DOI: 10.1038/nature08320. View

2.
Hibaoui Y, Grad I, Letourneau A, Sailani M, Dahoun S, Santoni F . Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol Med. 2013; 6(2):259-77. PMC: 3927959. DOI: 10.1002/emmm.201302848. View

3.
Amabile G, Welner R, Nombela-Arrieta C, DAlise A, Di Ruscio A, Ebralidze A . In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood. 2012; 121(8):1255-64. PMC: 3701251. DOI: 10.1182/blood-2012-06-434407. View

4.
Ellison D, Dalton J, Kocak M, Leigh Nicholson S, Fraga C, Neale G . Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011; 121(3):381-96. PMC: 3519926. DOI: 10.1007/s00401-011-0800-8. View

5.
Chambers S, Qi Y, Mica Y, Lee G, Zhang X, Niu L . Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol. 2012; 30(7):715-20. PMC: 3516136. DOI: 10.1038/nbt.2249. View